122 related articles for article (PubMed ID: 37935712)
1. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.
Buckley DN; Lewinger JP; Gooden G; Spillman M; Neuman M; Guo XM; Tew BY; Miller H; Khetan VU; Shulman LP; Roman L; Salhia B
Clin Cancer Res; 2023 Dec; 29(24):5196-5206. PubMed ID: 37812492
[TBL] [Abstract][Full Text] [Related]
2. Identification of estrogen response-associated STRA6+ granulosa cells within high-grade serous ovarian carcinoma by single-cell sequencing.
Liu X; Chen Z; Zhang L
Heliyon; 2024 Mar; 10(6):e27790. PubMed ID: 38509903
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues.
Yeganeh PN; Richardson C; Bahrani-Mostafavi Z; Tait DL; Mostafavi MT
Genes Cancer; 2017 Nov; 8(11-12):784-798. PubMed ID: 29321820
[TBL] [Abstract][Full Text] [Related]
4. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.
Pal R; Choudhury T; Ghosh M; Vernakar M; Nath P; Nasare VD
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38472557
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.
Coan M; Rampioni Vinciguerra GL; Cesaratto L; Gardenal E; Bianchet R; Dassi E; Vecchione A; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149579
[TBL] [Abstract][Full Text] [Related]
6. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
Niemira M; Erol A; Bielska A; Zeller A; Skwarska A; Chwialkowska K; Kuzmicki M; Szamatowicz J; Reszec J; Knapp P; Moniuszko M; Kretowski A
Sci Rep; 2023 Nov; 13(1):19287. PubMed ID: 37935712
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
9. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
10. Screening of Critical Genes Involved in Metastasis and Prognosis of High-Grade Serous Ovarian Cancer by Gene Expression Profile Data.
Wang R; Du X; Zhi Y
J Comput Biol; 2020 Jul; 27(7):1104-1114. PubMed ID: 31725318
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer.
Carvalho TM; Brasil GO; Jucoski TS; Adamoski D; de Lima RS; Spautz CC; Anselmi KF; Ozawa PMM; Cavalli IJ; Carvalho de Oliveira J; Gradia DF; Ribeiro EMSF
Front Genet; 2022; 13():865472. PubMed ID: 35846122
[TBL] [Abstract][Full Text] [Related]
14. miR-106b as an emerging therapeutic target in cancer.
Sagar SK
Genes Dis; 2022 Jul; 9(4):889-899. PubMed ID: 35685464
[TBL] [Abstract][Full Text] [Related]
15. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
